利伐沙班与阿司匹林持续抗凝预防复发性症状性静脉血栓栓塞的健康照护成本影响:EINSTEIN-CHOICE试验人群分析
本研究基于EINSTEIN-CHOICE试验数据,从美国管理式医疗视角评估利伐沙班与阿司匹林持续抗凝预防复发性症状性静脉血栓栓塞的成本影响。计算临床事件成本与药物成本之和作为总健康照护成本(2016年美元)。利伐沙班10 mg、20 mg和阿司匹林组每患者每月临床事件成本分别为123、243和381美元,但利伐沙班10 mg和20 mg组每患者每月总健康照护成本分别较阿司匹林高24美元和143美元。利伐沙班10 mg降价15%时,临床事件成本降低足以完全抵消更高的药物成本,总健康照护成本较阿司匹林低19美元。
要点
- 利伐沙班10 mg组每患者每月临床事件成本为123美元,利伐沙班20 mg组为243美元,阿司匹林组为381美元。
- 利伐沙班10 mg组每患者每月总健康照护成本较阿司匹林组高24美元,利伐沙班20 mg组较阿司匹林组高143美元。
- 利伐沙班10 mg降价15%时,其总健康照护成本较阿司匹林低19美元。
- 本研究为基于EINSTEIN-CHOICE试验数据的经济学分析,成本计算采用2016年美元和美国管理式医疗视角。
- 进行了单因素敏感性分析。
适用人群与场景
- EINSTEIN-CHOICE试验人群,即已完成初始抗凝治疗、需长期预防复发性症状性静脉血栓栓塞的患者。
研究设计与关键结果
- 研究类型为基于EINSTEIN-CHOICE试验数据的经济学分析,从美国管理式医疗视角计算总健康照护成本(2016年美元),总成本为临床事件成本与药物成本之和。
- 临床事件成本通过事件率乘以照护成本计算,1年Kaplan-Meier临床事件率(复发性肺栓塞、复发性深静脉血栓、全因死亡和出血)取自EINSTEIN-CHOICE试验,照护成本通过文献回顾确定。
- 药物成本为药品价格(批发采购成本)与治疗时长的乘积。
- 每患者每月临床事件成本:利伐沙班10 mg组123美元,利伐沙班20 mg组243美元,阿司匹林组381美元。
- 每患者每月总健康照护成本:利伐沙班10 mg组较阿司匹林组高24美元,利伐沙班20 mg组较阿司匹林组高143美元。
- 利伐沙班10 mg降价15%时,利伐沙班治疗患者更低的临床事件成本完全抵消更高的药物成本,总健康照护成本较阿司匹林低19美元。
- 进行了单因素敏感性分析。
证据类型、等级与局限
- 证据类型:基于随机对照试验EINSTEIN-CHOICE数据的成本分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,利伐沙班10 mg和20 mg与阿司匹林相比,持续治疗与更低的临床事件成本相关,但总健康照护成本更高;利伐沙班10 mg降价15%时总健康照护成本低于阿司匹林。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study assessed cost impact of continued anticoagulation therapy with rivaroxaban vs aspirin.
METHODS: Total health-care costs (2016 USD) associated with rivaroxaban and aspirin were calculated as the sum of clinical event costs and drug costs from a US managed care perspective. Clinical event costs were calculated by multiplying event rate by cost of care. One-year Kaplan-Meier clinical event rates for recurrent pulmonary embolism, recurrent DVT, all-cause mortality, and bleeding were obtained from EINSTEIN-CHOICE. Cost of care was determined by literature review. Drug costs were the product of drug price (wholesale acquisition cost) and treatment duration. A one-way sensitivity analysis was conducted.
RESULTS: Rivaroxaban users had lower per patient per month (PPPM) clinical event costs compared with aspirin users ($123, $243, and $381 for rivaroxaban 10 mg, rivaroxaban 20 mg, and aspirin, respectively). However, vs aspirin, PPPM total health-care costs were $24 higher for patients treated with rivaroxaban 10 mg ($143 higher for rivaroxaban 20 mg) due to higher cost of rivaroxaban. With a 15% discount for rivaroxaban 10 mg, the lower cost of clinical events for the rivaroxaban-treated patients more than fully offset the higher drug costs, and yielded a $19 lower total health-care cost.
CONCLUSIONS: Continued therapy with rivaroxaban 10 and 20 mg vs aspirin was associated with lower clinical event costs but higher total health-care costs; with a 15% drug discount rivaroxaban 10 mg had lower total health-care costs than aspirin.
参考来源
- Wells PS, Prins MH, Beyer-Westendorf J, et al. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. Chest. 2018. PMID: 30201406. doi:10.1016/j.chest.2018.08.1059
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。